Published in PLoS One on September 15, 2011
The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. PLoS One (2015) 1.48
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One (2013) 1.44
Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother (2013) 1.19
Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection (2013) 1.14
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med (2014) 1.08
Clinical and therapeutic aspects of candidemia: a five year single centre study. PLoS One (2015) 0.95
Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect Dis (2014) 0.87
Mortality in patients with early- or late-onset candidaemia. J Antimicrob Chemother (2012) 0.87
Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis (2014) 0.85
Galectin-3 plays an important role in protection against disseminated candidiasis. Med Mycol (2013) 0.85
High Recovery Rate of Non-albicans Candida Species Isolated From Burn Patients With Candidemia in Iran. Jundishapur J Microbiol (2015) 0.84
Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2p. PLoS One (2012) 0.83
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother (2013) 0.82
Antiproliferative effect and characterization of a novel antifungal peptide derived from human Chromogranin A. Exp Ther Med (2015) 0.81
Analysis of the clonality of Candida tropicalis strains from a general hospital in Beijing using multilocus sequence typing. PLoS One (2012) 0.81
Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections. Clin Microbiol Infect (2012) 0.79
Bloodstream infections in internal medicine. Virulence (2016) 0.78
Comparison Between Biofilm Production, Phospholipase and Haemolytic Activity of Different Species of Candida Isolated from Dental Caries Lesions in Children. J Clin Diagn Res (2016) 0.77
The epidemiological profile of candidemia at an Indian trauma care center. J Lab Physicians (2014) 0.77
A case of Candida glabrata severe urinary sepsis successfully treated with micafungin. Med Mycol Case Rep (2014) 0.77
Identification of New Antifungal Compounds Targeting Thioredoxin Reductase of Paracoccidioides Genus. PLoS One (2015) 0.77
A mouse model for Candida glabrata hematogenous disseminated infection starting from the gut: evaluation of strains with different adhesion properties. PLoS One (2013) 0.76
A Risk Score for Fluconazole Failure among Patients with Candidemia. Antimicrob Agents Chemother (2017) 0.75
Preventive Effects of Houttuynia cordata Extract for Oral Infectious Diseases. Biomed Res Int (2016) 0.75
Anti-candidal activity of a novel peptide derived from human chromogranin A and its mechanism of action against Candida krusei. Exp Ther Med (2015) 0.75
Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital. Braz J Microbiol (2016) 0.75
Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of Candida species. Antimicrob Agents Chemother (2014) 0.75
Candida utilis catheter-related bloodstream infection. Med Mycol Case Rep (2014) 0.75
Invasive Candidiasis due to Candida Norvegensis in a Liver Transplant Patient: Case Report and Literature Review. Infect Dis Rep (2014) 0.75
Inhibition of nucleic acid biosynthesis makes little difference to formation of amphotericin B-tolerant persisters in Candida albicans biofilm. Antimicrob Agents Chemother (2014) 0.75
Enterohemorrhagic Escherichia coli promotes the invasion and tissue damage of enterocytes infected with Candida albicans in vitro. Sci Rep (2016) 0.75
Optimization of the Expression Conditions of CGA-N46 in Bacillus subtilis DB1342(p-3N46) by Response Surface Methodology. Interdiscip Sci (2015) 0.75
Nosocomial candidiasis in Rio de Janeiro State: Distribution and fluconazole susceptibility profile. Braz J Microbiol (2015) 0.75
Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis (2014) 0.75
Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Ann Clin Microbiol Antimicrob (2016) 0.75
Low caspofungin exposure in patients in the Intensive Care Unit. Antimicrob Agents Chemother (2016) 0.75
Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid). Nanotechnol Sci Appl (2017) 0.75
Interference of confounding factors on the use of (1,3)-beta-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit. Eur J Clin Microbiol Infect Dis (2014) 0.75
Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei. Exp Ther Med (2017) 0.75
Candidemia in patients with prolonged fever in Kashan, Iran. Curr Med Mycol (2016) 0.75
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis (2004) 20.99
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother (2005) 5.35
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis (2006) 5.27
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis (1992) 4.98
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis (2009) 4.59
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis (1999) 3.39
Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol (2002) 3.30
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis (2004) 3.25
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis (2004) 3.22
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol (2004) 2.06
Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol (2002) 1.92
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents (2006) 1.77
Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg (2000) 1.73
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med (1997) 1.70
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis (1999) 1.57
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis (2011) 1.57
Candidemia in Finland, 1995-1999. Emerg Infect Dis (2003) 1.55
Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol (2009) 1.52
Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis (2000) 1.45
Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect (2002) 1.42
Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol (1998) 1.42
Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses (2002) 1.40
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother (2005) 1.34
Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) (2002) 1.33
Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis (2010) 1.18
Retracted Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol (2010) 1.16
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother (2009) 1.00
Trends and sources of nosocomial fungaemia. Mycoses (1995) 0.98
Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol (2002) 0.87
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (2005) 1.63
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol (2006) 1.30
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J (2006) 1.25
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab (2006) 1.23
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs (2008) 1.21
Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem (2002) 1.20
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.08
The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clin Biochem (2011) 1.08
Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc Natl Acad Sci U S A (2013) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents (2009) 1.04
Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol (2009) 1.03
Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther (2012) 1.03
Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis (2010) 1.02
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis (2009) 1.02
Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol (2007) 1.01
Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther (2012) 1.00
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother (2009) 1.00
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents (2010) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J (2003) 0.96
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Voriconazole in clinical practice. J Chemother (2012) 0.96
Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis (2012) 0.96
Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol (2012) 0.96
Combination therapy for invasive aspergillosis. Clin Infect Dis (2004) 0.95
Current status of newer carbapenems. Curr Med Chem (2009) 0.95
Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis (2013) 0.95
Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. Br J Haematol (2003) 0.95
Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens) (2007) 0.92
Middle molecule and small protein removal in children on peritoneal dialysis. Kidney Int (2002) 0.92
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. Curr HIV Res (2013) 0.90
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care (2010) 0.90
Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiol (2007) 0.90
Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother (2005) 0.89
Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities. Int J Legal Med (2012) 0.89
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother (2006) 0.88
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. J Antimicrob Chemother (2013) 0.88
A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis (2004) 0.88
Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem (2008) 0.88
Amnioexchange for fetuses with gastroschisis: is it effective? J Pediatr Surg (2007) 0.87
Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. Int J Antimicrob Agents (2009) 0.87
Clinical metabolomics and urinary NGAL for the early prediction of chronic kidney disease in healthy adults born ELBW. J Matern Fetal Neonatal Med (2011) 0.87
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care (2011) 0.86
Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect Dis (2011) 0.86
Bordetella holmesii endocarditis in a patient with systemic lupus erythematous treated with immunosuppressive agents. J Chemother (2012) 0.84
Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother (2014) 0.84
Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. J Zhejiang Univ Sci B (2009) 0.84
Will new antimicrobials overcome resistance among Gram-negatives? Expert Rev Anti Infect Ther (2011) 0.84
Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol (2008) 0.84
Identification of a New Delhi metallo-β-lactamase-4 (NDM-4)-producing Escherichia coli in Italy. BMC Microbiol (2014) 0.84
Adherence to international and national recommendations for the prevention of surgical site infections in Italy: results from an observational prospective study in elective surgery. Am J Infect Control (2012) 0.83
Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol (2006) 0.83
Bacterial infections in hematopoietic stem cell transplantation recipients. Curr Opin Hematol (2014) 0.83
Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis (2011) 0.83
Differential diagnosis of pleural mesothelioma using Logic Learning Machine. BMC Bioinformatics (2015) 0.82
Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother (2013) 0.82
Measles outbreak in adults in Italy. Infez Med (2011) 0.82
Is 1H NMR metabolomics becoming the promising early biomarker for neonatal sepsis and for monitoring the antibiotic toxicity? J Chemother (2013) 0.82
Urinary metabolomics of bronchopulmonary dysplasia (BPD): preliminary data at birth suggest it is a congenital disease. J Matern Fetal Neonatal Med (2014) 0.81
Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience. J Assoc Nurses AIDS Care (2015) 0.81
Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system? J Antimicrob Chemother (2011) 0.81
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother (2009) 0.81
Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Rep (2009) 0.81
Neonatal nephrology and laboratory medicine: an effective interdisciplinary model to improve the outcome in neonatal intensive care unit. J Matern Fetal Neonatal Med (2011) 0.81
Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. Clin Chim Acta (2011) 0.81